

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.				
1. REPORT DATE (DD-MM-YYYY) 2010		2. REPORT TYPE Open Literature		3. DATES COVERED (From - To)
4. TITLE AND SUBTITLE Reactivation of brain acetylcholinesterase by monoisonitrosoacetone increases the therapeutic efficacy against nerve agents in guinea pigs		5a. CONTRACT NUMBER		
		5b. GRANT NUMBER		
		5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Skovira, JW, O'Donnell, JC, Koplovitz, I, Kan, RK, McDonough, JH, Shih, T-M		5d. PROJECT NUMBER		
		5e. TASK NUMBER		
		5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) US Army Medical Research Institute of Chemical Defense ATTN: MCMR-CDR-P 3100 Ricketts Point Road Aberdeen Proving Ground, MD 21010-5400		8. PERFORMING ORGANIZATION REPORT NUMBER USAMRICD-P09-028		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) US Army Medical Research Institute of Chemical Defense ATTN: MCMR-CDZ-I 3100 Ricketts Point Road Aberdeen Proving Ground, MD 21010-5400		10. SPONSOR/MONITOR'S ACRONYM(S)		
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				
13. SUPPLEMENTARY NOTES Published in Chemico-Biological Interactions ,187, 318-324, 2010. This research was supported by the Defense Threat Reduction Agency - Joint Service and Technology Office, Medical Science and Technology Division.				
14. ABSTRACT See reprint.				
15. SUBJECT TERMS Acetylcholinesterase, Brain, Central nervous system, Cholinesterase reactivation, Cyclosarin, Guinea pig, Monoisonitrosoacetone, Nerve agents, Oximes, Pralidoxime, Protective ratio, Sarin, Survival, VX				
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UNLIMITED	18. NUMBER OF PAGES 7
a. REPORT UNCLASSIFIED	b. ABSTRACT UNCLASSIFIED	c. THIS PAGE UNCLASSIFIED		
				19a. NAME OF RESPONSIBLE PERSON Tsung-Ming Shih
				19b. TELEPHONE NUMBER (include area code) 410-436-3414



Reactivation of brain acetylcholinesterase by monoisonitrosoacetone increases the therapeutic efficacy against nerve agents in guinea pigs[☆]

Jacob W. Skovira, John C. O'Donnell, Irwin Koplovitz, Robert K. Kan,
John H. McDonough, Tsung-Ming Shih^{*}

Pharmacology Branch, Research Division, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010-5400, USA

ARTICLE INFO

Article history:

Available online 15 March 2010

Keywords:

Acetylcholinesterase
Brain
Central nervous system
Cholinesterase reactivation
Cyclosarin
Guinea pig
Monoisonitrosoacetone
Nerve agents
Oximes
Pralidoxime
Protective ratio
Sarin
Survival
VX

ABSTRACT

Current oxime therapies do not readily cross the blood–brain barrier to reactivate organophosphorus nerve agent-inhibited cholinesterase (ChE) within the CNS. We investigated the ability of monoisonitrosoacetone (MINA), a tertiary oxime, to reactivate ChE inhibited by the nerve agent sarin (GB), cyclosarin (GF), or VX, in peripheral tissues and brain of guinea pigs and determined whether reactivation in the CNS will enhance protection against the lethal effects of these three agents. In the reactivation experiment, animals were pretreated with atropine methylnitrate (1.0 mg/kg, i.m.) 15 min prior to subcutaneous (s.c.) challenge with 1.0× LD₅₀ of GB, GF, or VX. Fifteen minutes later animals were treated intramuscularly (i.m.) with MINA (ranging from 22.1 to 139.3 mg/kg) or 2-PAM (25.0 mg/kg). At 60 min after nerve agent, CNS (brainstem, cerebellum, cortex, hippocampus, midbrain, spinal cord, and striatum) and peripheral (blood, diaphragm, heart, and skeletal muscle) tissues were collected for ChE analysis. MINA reactivated nerve agent-inhibited ChE in the CNS and peripheral tissues in a dose-dependent manner in the following order of potency: GB > GF > VX. In a survival experiment, animals were injected i.m. with atropine sulfate (0.5 mg/kg), 2-PAM (25.0 mg/kg), or MINA (35.0, 60.0, or 100.0 mg/kg) alone or in combination 1 min after challenge with varying s.c. doses of GB, GF, or VX to determine the level of protection. The rank order of MINA's efficacy in guinea pigs against nerve agent lethality was the same as for reactivation of inhibited ChE in the CNS. These data show that MINA is capable of reactivating nerve agent-inhibited ChE and that the extent of ChE reactivation within the CNS strongly relates to its therapeutic efficacy.

Published by Elsevier Ireland Ltd.

1. Introduction

Organophosphorus nerve agents, such as sarin (GB), cyclosarin (GF), and VX, are potent inhibitors of the enzyme cholinesterase (ChE). Their toxic effects are due to hyperactivity of the cholinergic system as a result of ChE, especially acetylcholinesterase (AChE) inhibition, and the subsequent increase in the level of the neurotransmitter acetylcholine (ACh) in the brain and

periphery [1]. Severe inhibition of ChE in the brain initiates seizures, which if not terminated result in neuropathology and contribute to the incapacitating effects of these agents [2,3].

In the event of nerve agent poisoning, immediate medical therapy with atropine sulfate to antagonize the effects of ACh at muscarinic receptors, and an oxime, such as 2-PAM (pralidoxime), P2S, obidoxime (Toxogonin®), or HI-6, to reactivate any unaged, inhibited enzyme [1,4–6] is used to prevent lethality. These oximes possess positively charged quaternary nitrogen structures, cannot readily cross the blood–brain barrier (BBB), and reactivate ChE only in the periphery. Thus, their inability to enter the central nervous system (CNS) and reactivate nerve agent-inhibited brain ChE is a major limitation of current oxime therapy. Monoisonitrosoacetone (MINA) is a tertiary oxime that was investigated in the 1950s. It is highly lipid soluble and can readily penetrate the BBB [7], and is able to reactivate ChE within the CNS [7,8]. When used alone or in combination with atropine sulfate, MINA was shown to raise the LD₅₀ doses of GB in several animal species [8–13]. Unfortunately, this tertiary oxime was not pursued further, due to reports that quaternary pyridinium oximes (e.g., 2-PAM) were more potent

[☆] Research was conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations relating to animals and experiments involving animals and adhered to principles stated in the *Guide for the Care and Use of Laboratory Animals*, by the Institute of Laboratory Animal Resources, National Research Council. The facility where this research was conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as reflecting the views of the Department of the Army or the Department of Defense.

^{*} Corresponding author at: US Army Medical Research Institute of Chemical Defense, ATTN: MCMR-CDR-P (Dr. T.-M. Shih), 3100 Ricketts Point Road, Aberdeen Proving Ground, MD 21010-5400, USA. Tel.: +1 410 436 3414; fax: +1 410 436 2072.

E-mail address: tsungming.a.shih@us.army.mil (T.-M. Shih).

reactivators of phosphorylated ChE by several orders of magnitude [14].

We recently showed that MINA reactivated ChE in the brain, reduced toxic signs, improved survival, and prevented or terminated seizures following GB intoxication in guinea pigs [15,16]. These findings support previous reports that protection of ChE enzyme activity in the brain as well as in peripheral tissues with centrally acting reversible ChE inhibitors (such as physostigmine) improved survival, prevented seizure occurrence, and reduced neuropathology and behavioral consequences of nerve agent intoxication more effectively than peripherally acting reversible ChE inhibitors, such as pyridostigmine [17–19]. The present study was designed to further evaluate the capability of MINA to reactivate ChE in discrete brain regions when given after the maximal inhibition of this enzyme by the nerve agents GB, GF, and VX was reached [20]. We also conducted a survival experiment, first to see if there was a relationship between CNS reactivation by MINA and survival, and secondly, to examine the effects of combining MINA with 2-PAM in the treatment regimen following exposure to these nerve agents.

2. Materials and methods

2.1. Subjects

Male Hartley guinea pigs (CrI:(HA) BR COBS) weighing 250–300 g were purchased from Charles River Labs (Kingston, NY). They were housed in individual cages in temperature ($21 \pm 2^\circ\text{C}$) and humidity ($50 \pm 10\%$) controlled quarters that were maintained on a 12-h light–dark schedule (with lights on at 0600 h). Laboratory chow and filtered tap water were freely available whenever the animals were in home cages.

2.2. Materials

Saline (U.S.P.), AttaneTM (Isoflurane, U.S.P.), and heparin sodium were purchased from Braun Medical, Inc. (Irvine, CA), Minrad, Inc. (Bethlehem, PA), and U.S.P., Inc. (Rockville, MD), respectively. 2-PAM was purchased from Ayerst Labs, Inc. (New York, NY). MINA, acetylthiocholine iodide, atropine methylnitrate, and atropine sulfate were purchased from Sigma–Aldrich (St. Louis, MO). Bicinchoninic acid (BCA) Protein Assay Reagent A and Reagent B were purchased from Pierce Biotechnology, Inc. (Rockford, IL). Sarin (GB; isopropyl methylphosphonofluoridate), cyclosarin (GF; cyclohexyl methylphosphonofluoridate), and VX (O-ethyl S-(2-(diisopropylamino)ethyl) methylphosphonothioate) were obtained from the US Army Edgewood Chemical Biological Center (Aberdeen Proving Ground, MD). Nerve agents were diluted in ice-cold saline prior to subcutaneous (s.c.) injection. In the reactivation experiment atropine methylnitrate and oxime compounds were prepared in saline individually for intramuscular (i.m.) injection. In the survival experiment, atropine sulfate and 2-PAM were admixed and MINA was injected separately. Injection volumes were 0.50 ml/kg for nerve agent and all treatment drugs.

2.3. Reactivation experiment

One to three days prior to the experiment, control blood samples (~0.5 ml) were drawn using the toenail clip method [21] and collected into a 1.0-ml microfuge tube containing 50 μl of heparin sodium (15 U/ml) to determine baseline ChE activity in whole blood (WB) and red blood cells (RBC). On the day of the study, guinea pigs were pretreated with atropine methylnitrate (1.0 mg/kg, i.m.) 15 min prior to a nerve agent exposure to minimize peripheral toxic effects. Atropine methylnitrate is a peripherally acting muscarinic

receptor blocker that does not affect ChE activity. Animals were injected s.c. with either saline (0.5 ml/kg) or a $1.0 \times \text{LD}_{50}$ dose of GB (42.0 $\mu\text{g/kg}$), GF (57.0 $\mu\text{g/kg}$), or VX (8.0 $\mu\text{g/kg}$). The severity of toxic signs of each animal was scored at 13 min after nerve agent. Fifteen minutes after nerve agent injection, when the inhibition of ChE activity by these nerve agents reached maximum [20], saline (0.5 ml/kg), 2-PAM (25.0 mg/kg), or MINA (22.1, 35.0, 55.5, 87.9, or 139.3 mg/kg) was given i.m. Control animals received s.c. saline (no nerve agent) and i.m. saline (no oximes). There were eight animals assigned to each treatment group.

Sixty minutes after s.c. saline or nerve agent administration, the animals were deeply anesthetized with isoflurane and euthanized by decapitation. Blood (~0.5 ml) was collected into a 1.0-ml microfuge tube containing 50 μl of heparin sodium solution (15 U/ml). For the WB samples, 20 μl of blood was diluted 1:25 in 1% Triton-X100 solution. For the RBC samples, the original blood sample was centrifuged for 5 min at 14,000 rpm, and 10 μl of the packed RBC was then diluted 1:50 in 1% Triton-X100 solution. Brain regions (brainstem, cerebellum, cortex, hippocampus, midbrain, spinal cord and striatum) and peripheral tissue (diaphragm, heart, and skeletal muscle) were dissected. Brain samples were diluted 1:20, while peripheral samples were diluted 1:5, in 1% Triton-X100 solution and then homogenized. The homogenates were then centrifuged ($31,000 \times g$ at 4°C ; 20 min for brain and 30 min for peripheral tissues) and the supernatant decanted and kept frozen at -80°C until ChE analysis.

2.3.1. Toxic signs test

At approximately 13 min and 58 min after GB, GF, or VX injection, guinea pigs were observed for signs of cholinergic toxicity, including secretions (salivation or lacrimation), motor deficits, and general state (activity and coordination) based on the procedures described earlier [22]. Animals were scored for absence [0] or presence [1] of each of the following signs: salivation, lacrimation, and nystagmus. General motor signs were assessed on the basis of a 0–3 scoring scale: normal=0, fasciculation=1, tremor=2, or convulsion=3. The guinea pig was allowed to walk on the bench top, and general state was also assessed on a 0–3 scoring scale: normal=0, mild uncoordination=1, impaired movement/righting reflex=2, or prostration/no righting reflex=3. A cumulative score was then calculated by tabulating the salivation, lacrimation, nystagmus, general motor and general state scores for each subject. The maximal attainable score was 9. A cumulative score was categorized as mild intoxication [0–3.0], moderate intoxication [3.1–6.0] and severe intoxication [6.1–9.0].

2.3.2. ChE activity assay

Processed blood, tissue and brain samples were analyzed for ChE activity and protein concentrations according to the methods described by Shih et al. [21,22], based on the colorimetric method of Ellman et al. [23] and a BCA protein assay (Pierce Biotechnology, Inc.). Briefly, in the modified Ellman method, 7 μl of sample (or enzyme standard), 20 μl H_2O , 200 μl DTNB reagent, and 30 μl acetylthiocholine iodide substrate was added to each well of a 96 well microplate (samples run in triplicate), and mean activity was determined by applying Beer–Lambert's Law, incorporating the observed change in absorbance, known extinction coefficient of the DTNB ion, path-length correction, and dilution factor. All sample values were well within the linear range of the standard curve. Protein concentrations of brain and tissue samples in the BCA assay were determined by interpolating from a standard curve, and applied to ChE activity from the same tissue sample for final values in $\mu\text{mol/g}$ protein/min. Each tissue sample was normalized as a percentage of the average saline control value for that tissue type. Post-exposure blood enzyme activity ($\mu\text{mol/ml/min}$)

Table 1ChE reactivation by oxime treatments in brain regions, peripheral tissues and blood components following exposure to GB, GF, and VX.^a

(A) Brain regions (brainstem, cerebellum, cortex, hippocampus, midbrain, spinal cord, striatum)								
Agent	Treatment (mg/kg)	Brainstem	Cerebellum	Cortex	Hippocampus	Midbrain	Spinal Cord	Striatum
GB	Saline	08.9 ± 1.1	06.2 ± 0.7	05.9 ± 0.6	13.6 ± 1.4	07.8 ± 0.8	21.4 ± 3.5	13.5 ± 1.9
	2-PAM (25.0)	12.7 ± 0.8	08.9 ± 1.0	10.1 ± 0.9	14.9 ± 1.7	10.8 ± 0.9	22.6 ± 2.3	17.7 ± 2.8
	MINA (22.1)	14.8 ± 2.3	10.2 ± 1.5	13.2 ± 1.7	18.8 ± 4.4	14.2 ± 1.6	23.1 ± 3.1	22.1 ± 3.3
	MINA (35.0)	18.2 ± 2.2	13.3 ± 1.6	14.9 ± 2.4*	21.4 ± 3.1	16.9 ± 1.8	26.3 ± 2.7	25.1 ± 3.2
	MINA (55.5)	24.9 ± 4.3*	20.7 ± 3.8*	22.4 ± 3.0*	27.1 ± 5.5	26.1 ± 4.5*	32.5 ± 4.7	32.2 ± 5.5*
	MINA (87.9)	27.3 ± 3.9*	24.6 ± 2.2*	21.7 ± 2.4*	34.8 ± 3.5*	27.7 ± 2.5*	30.6 ± 4.4	34.9 ± 4.6*
	MINA (139.3)	33.4 ± 4.9*	33.0 ± 3.9*	31.7 ± 3.6*	32.8 ± 6.3*	35.6 ± 4.1*	40.7 ± 4.2*	44.7 ± 5.6*
GF	Saline	23.2 ± 1.7	12.7 ± 1.1	13.5 ± 4.3	28.7 ± 2.7	19.2 ± 1.4	31.8 ± 2.4	27.6 ± 3.6
	2-PAM (25.0)	20.7 ± 1.6	11.3 ± 1.8	08.5 ± 1.0	23.4 ± 2.5	15.1 ± 1.7	34.7 ± 3.1	27.0 ± 3.5
	MINA (22.1)	28.8 ± 1.9	16.1 ± 1.3	14.5 ± 1.7	33.8 ± 3.9	24.7 ± 1.9	41.9 ± 1.2	26.5 ± 2.9
	MINA (35.0)	30.6 ± 1.6	16.5 ± 1.1	15.2 ± 1.7	36.1 ± 2.1	23.9 ± 1.6	38.9 ± 1.8	36.1 ± 3.4
	MINA (55.5)	35.1 ± 3.6*	20.8 ± 2.7*	24.7 ± 2.8	38.3 ± 3.9	32.7 ± 2.1*	43.2 ± 3.0*	43.6 ± 5.4
	MINA (87.9)	33.3 ± 1.2*	17.4 ± 1.3	23.7 ± 3.0	36.4 ± 2.8	30.0 ± 1.4*	43.4 ± 1.3*	33.1 ± 2.7
	MINA (139.3)	39.9 ± 1.7*	24.0 ± 2.5*	29.2 ± 2.8*	43.7 ± 2.4*	35.5 ± 2.3*	47.3 ± 3.2*	39.0 ± 5.4
VX	Saline	25.4 ± 1.8	15.2 ± 1.3	10.4 ± 0.5	13.5 ± 0.9	18.8 ± 1.8	31.5 ± 3.6	38.4 ± 4.7
	2-PAM (25.0)	25.4 ± 1.4	14.7 ± 1.1	13.9 ± 1.6	21.3 ± 2.2	17.8 ± 0.8	35.1 ± 1.5	38.9 ± 3.6
	MINA (22.1)	23.6 ± 1.3	18.0 ± 1.6	11.8 ± 1.1	17.8 ± 1.3	23.3 ± 3.1	32.6 ± 2.9	45.4 ± 3.3
	MINA (35.0)	24.9 ± 2.2	18.3 ± 2.2	11.6 ± 0.5	19.9 ± 1.7	20.7 ± 1.7	35.5 ± 4.3	43.5 ± 3.7
	MINA (55.5)	27.1 ± 3.0	24.7 ± 3.7	16.5 ± 1.9	23.9 ± 2.1*	25.2 ± 3.1	36.4 ± 4.7	46.9 ± 4.8
	MINA (87.9)	32.3 ± 2.5	26.2 ± 2.4	16.2 ± 1.4	27.3 ± 1.7*	26.0 ± 2.4	36.7 ± 5.0	49.9 ± 4.5
	MINA (139.3)	38.8 ± 4.9*	32.2 ± 5.0*	26.2 ± 2.6*	36.7 ± 4.0*	34.4 ± 3.6*	50.7 ± 8.6	56.5 ± 7.0
(B) Peripheral tissues (diaphragm, heart, skeletal muscle) and Blood (red blood cells and whole blood)								
Agent	Treatment (mg/kg)	Diaphragm	Heart	Skeletal muscle	Red blood cells	Whole blood		
GB	Saline	19.9 ± 1.8	11.4 ± 0.6	22.8 ± 2.5	08.9 ± 2.1	10.8 ± 1.6		
	2-PAM (25.0)	62.0 ± 2.7*	61.4 ± 3.4*	52.2 ± 4.3*	62.0 ± 3.5*	69.0 ± 2.8*		
	MINA (22.1)	17.7 ± 3.3	14.5 ± 1.1	38.5 ± 8.3	09.7 ± 0.5	08.9 ± 0.3		
	MINA (35.0)	29.5 ± 5.0	16.8 ± 1.1	36.8 ± 3.4	14.2 ± 0.9	12.1 ± 0.6		
	MINA (55.5)	31.0 ± 4.3	21.4 ± 2.0*	43.9 ± 6.3*	25.3 ± 4.7*	21.9 ± 5.4*		
	MINA (87.9)	38.2 ± 3.4*	23.8 ± 1.0*	38.1 ± 4.5	30.7 ± 1.5*	25.3 ± 1.3*		
	MINA (139.3)	43.8 ± 4.1*	31.7 ± 2.4*	46.9 ± 4.3*	43.3 ± 5.0*	35.1 ± 3.4*		
GF	Saline	39.2 ± 3.0	23.8 ± 0.7	45.7 ± 2.6	06.2 ± 1.6	10.3 ± 1.3		
	2-PAM (25.0)	38.8 ± 1.9	32.8 ± 1.9	32.4 ± 2.2	07.9 ± 1.7	22.2 ± 1.4*		
	MINA (22.1)	41.1 ± 2.6	30.9 ± 1.6	38.5 ± 4.5	03.6 ± 0.4	18.6 ± 1.0		
	MINA (35.0)	47.2 ± 1.8	36.0 ± 1.5*	48.1 ± 2.3	04.1 ± 0.6	24.1 ± 1.9*		
	MINA (55.5)	52.4 ± 2.2*	44.4 ± 2.7*	52.7 ± 3.9	08.1 ± 2.3	34.5 ± 2.5*		
	MINA (87.9)	53.8 ± 3.8*	51.3 ± 3.5*	50.1 ± 4.2	08.8 ± 1.2	45.8 ± 3.2*		
	MINA (139.3)	59.9 ± 2.9*	58.5 ± 2.7*	56.4 ± 3.2	11.6 ± 0.8	47.6 ± 2.5*		
VX	Saline	28.2 ± 1.9	22.9 ± 1.3	25.9 ± 1.0	13.3 ± 3.2	25.7 ± 3.5		
	2-PAM (25.0)	46.0 ± 2.1*	45.2 ± 1.5*	26.7 ± 3.3	51.2 ± 2.9*	55.6 ± 0.8*		
	MINA (22.1)	27.9 ± 1.4	26.2 ± 1.4	34.9 ± 2.8*	12.8 ± 2.3	26.3 ± 3.8		
	MINA (35.0)	27.9 ± 1.7	24.8 ± 1.1	30.0 ± 1.4	12.6 ± 2.0	24.1 ± 0.9		
	MINA (55.5)	33.4 ± 2.0	30.9 ± 1.8*	33.3 ± 2.1	17.3 ± 2.6	28.4 ± 1.9		
	MINA (87.9)	33.2 ± 1.2	33.7 ± 2.4*	34.2 ± 1.1	23.7 ± 3.1	31.2 ± 1.2		
	MINA (139.3)	46.6 ± 2.7*	44.7 ± 2.1*	44.6 ± 1.5*	47.1 ± 3.0*	40.7 ± 3.5*		

^a Effects of nerve agent and oxime treatments on brain regions (A) and peripheral tissue and blood (B) ChE activity in the guinea pig. Saline, MINA, or 2-PAM was given intramuscularly 15 min after a 1.0 × LD₅₀ subcutaneous dose of GB, GF, or VX. Samples were collected at 60 min after nerve agent administration. ChE activity in brain and peripheral tissue was expressed as percentage of control ChE activity for each tissue. ChE activity in RBC and WB was expressed as percentage of individual baseline ChE activity. The baseline ChE activity was obtained 1–3 days prior to experimental treatment. Total ChE activity was expressed as mean ± SEM (% of control group) with 6–8 animals/group.

* Significantly different from saline at 60 min, $p < 0.05$.

was normalized as a percentage of each sample's corresponding baseline activity.

2.4. Survival experiments

Guinea pigs were challenged s.c. with various doses of GB, GF, or VX to establish dose–lethality curves and to estimate a 24-h nerve agent LD₅₀ for each treatment regimen. Treatments were injected i.m. in a hind limb 1 min after nerve agent challenge and consisted of one of the following: atropine sulfate (0.5 mg/kg), 2-PAM (25.0 mg/kg), MINA (35.0, 60.0 or 100.0 mg/kg), atropine sulfate + 2-PAM, atropine sulfate + MINA, or atropine sulfate + 2-PAM + MINA. The dose–lethality curves were generated using a sequential, up–down, stage design [24–26]. With this design each

stage consisted of 3–6 nerve agent doses with 1–4 animals/dose selected to cover the predicted range of lethality from 0% to 100% for each nerve agent and treatment regimen. Nerve agent doses after the first stage were based on the lethality responses from the previous stage(s). After each stage, probit dose–response models using maximum likelihood were fitted to the combined data for all stages [27]. Three or four stages and 19–42 animals were used to generate each dose–lethality curve.

The doses of atropine sulfate and 2-PAM used in this study were human relevant doses of these drugs. The atropine sulfate dose (0.5 mg/kg) was the human equivalent of three 2-mg atropine autoinjectors (MARK I Kit®) based on inter-species body surface area scaling formulas recommended by the Food and Drug Administration [28]. The 2-PAM dose (25.0 mg/kg) was the human

Table 2Summary of the significant ChE reactivation by oxime treatments in brain regions, peripheral tissues and blood components following exposure to GB, GF, and VX.^a

	2-PAM (25.0) ^b	MINA (22.1)	MINA (35.0)	MINA (55.5)	MINA (87.9)	MINA (139.3)
(A) Brain regions (brainstem, cerebellum, cortex, hippocampus, midbrain, spinal cord, stnatum)						
GB	—	—	+	+++++	+++++	+++++
GF	—	—	—	++++	+++	+++++
VX	—	—	—	+	+	++++
(B) Peripheral tissues (diaphragm, heart, skeletal muscle)						
GB	+++	—	—	++	++	+++
GF	—	—	+	++	++	++
VX	++	+	—	+	+	+++
(C) Blood (red blood cells and whole blood)						
GB	++	—	—	++	++	++
GF	+	—	+	+	+	+
VX	++	—	—	—	—	++

^a For each of the brain regions (A), peripheral tissues (B), or blood components (C), an oxime treatment that significantly reactivated a nerve agent-inhibited ChE activity was assigned a “+” sign. When an oxime treatment did not significantly reactivate a nerve agent-inhibited ChE in any tissue, it was assigned a “—” sign.

^b Numbers inside the pairs of parentheses indicated the dosages (mg/kg, i.m.) of oxime administered 15 min after challenge with 1.0× LD₅₀ dose of GB, GF, or VX. Animals received atropine methylnitrate (1.0 mg/kg, i.m.) 15 min prior to nerve agent exposure.

equivalent of three 600-mg 2-PAM autoinjectors (MARK I Kit®) on a mg/kg basis in a 70-kg individual [29]. In the reactivation experiment, a full dose range for MINA (22.1, 35.0, 55.5, 87.9, or 139.3 mg/kg) was conducted, while in the survival experiment the MINA doses used (35.0, 60.0 or 100.0 mg/kg, i.m.) were those that resulted in approximately 10–20% reactivation of regional brain ChE.

2.5. Data analysis

In the reactivation experiment, statistical analysis of toxic sign scores was performed using a Kruskal–Wallis test to compare across treatments. A Dunn test was then performed as a post-test for multiple comparisons. Differences in the incidence of toxic signs between treatment groups were evaluated using Fisher's exact test. A Mann–Whitney test was performed to compare toxic sign scores between the 13-min and 58-min scoring times.

For ChE activity statistical analysis of enzymatic activities was performed using a one-way ANOVA to compare across treatments. A post hoc Tukey test was used for multiple comparisons. Statistical significance for all tests was defined as $p < 0.05$.

We divided the ChE reactivation data into three compartments: the brain regions, the peripheral tissues, and the blood components. A “+” sign was assigned for each of the brain regions, peripheral tissues, or blood components, when an oxime treatment significantly reactivated nerve agent-inhibited ChE. For example, if an oxime treatment significantly reactivated ChE in all seven brain regions

its cell received “+++++” maximum, in all three peripheral tissues its cell received “+++” maximum, or in the two components of blood its cell received “++” maximum. When an oxime treatment did not significantly reactivate a nerve agent-inhibited ChE in any tissue, it was assigned a “—” sign.

In the survival experiment, custom-designed probit models (Battelle Memorial Institute, Columbus, OH) and SAS NLIN (V 6.12) were used to calculate LD₅₀s, 95% confidence intervals (CI), and for comparison of the LD₅₀s. LD₅₀ ratio (or protective ratio [PR]) was defined as the nerve agent LD₅₀ for a particular treatment regimen divided by the nerve agent LD₅₀ for atropine sulfate treatment. LD₅₀ ratios were considered significantly different ($p < 0.05$) from each other, by definition, if their 95% CI did not include the number 1.0.

3. Results

3.1. Reactivation experiment

3.1.1. Signs of toxicity

About 60 min after exposure to a 1.0× LD₅₀ s.c. dose of GB, GF, or VX, guinea pigs not receiving any oxime (saline-treated group) therapy showed a high incidence of cholinergic toxic signs (GB 92%; GF 100%; and VX 78%). The average toxic sign scores for GB- and VX-exposed untreated animals significantly increased from the 13-min to the 58-min scoring time (from 2.62 to 5.00 and from 0.33 to 3.44, respectively) and rated in the moderate range. Toxic sign scores for GF-exposed untreated animals also rated in the moderate

Table 3A

Efficacy of MINA treatment against nerve agents in guinea pigs.

GRP#	Treatment (mg/kg) ^a	LD ₅₀ ratios ^b (95% CI)		
		GB	GF	VX
1	Atr (0.5)	1.0 ^c	1.0 ^c	1.0 ^c
2	2-PAM (25)	2.0 (1.3–3.3)	1.0 (0.8–1.4)	2.3 (1.4–3.8)
3	Atr + 2-PAM	3.3 (2.2–4.9)	1.1 (0.8–1.4)	2.6 (1.5–4.6)
4	MINA (35)	3.6 (3.1–4.1)	1.4 (1.1–1.8)	1.2 (1.1–1.3)
5	MINA (60)	7.3 (5.7–9.3)	2.4 (1.9–3.1)	1.4 (1.3–1.6)
6	MINA (100)	—	3.7 (2.6–5.1)	1.8 (1.7–2.0)
7	Atr + MINA (35)	4.4 (2.9–6.6)	1.4 (1.1–1.9)	1.0 (0.9–1.1)
8	Atr + MINA (60)	7.8 (5.2–11.7)	2.1 (1.6–2.8)	1.3 (1.1–1.7)
9	Atr + MINA (100)	—	4.1 (3.1–5.6)	2.3 (2.0–2.7)
10	Atr + 2-PAM + MINA (35)	16.7 (6.3–44.1)	1.6 (1.1–2.2)	2.9 (2.4–3.5)
11	Atr + 2-PAM + MINA (60)	14.2 (9.1–22.2)	3.0 (1.9–4.5)	4.4 (3.0–6.4)
12	Atr + 2-PAM + MINA (100)	—	3.7 (2.7–5.1)	6.2 (5.2–7.4)

^a Treatment was given i.m. 1 min after s.c. challenge with nerve agent.

^b The LD₅₀ ratio was defined as the nerve agent LD₅₀ for a particular treatment regimen divided by the nerve agent LD₅₀ for atropine sulfate (Atr) treatment.

^c The LD₅₀ doses for agent alone are 42.0, 57.0, and 8.0 µg/kg, and the LD₅₀ doses for agent plus Atr treatment are 40.2, 52.1, and 9.0 µg/kg for GB, GF, and VX, respectively.

Table 3BSignificant ($p < 0.05$) LD₅₀ ratio comparisons.

GRP#	Treatment (mg/kg)	Significant group (GRP#) comparisons ^a		
		GB	GF	VX
1	Atr (0.5)	–	–	–
2	2-PAM (25)	1	NS	1,4,7,8
3	Atr + 2-PAM	1	NS	1,4,5,7,8
4	MINA (35)	1,2	1,2,3	1,7
5	MINA (60)	1,2,3,4	1,2,3,4,7,10	1,4,7
6	MINA (100)	NT	1,2,3,4,5,6,7,8,10	1,4,5,7,8
7	Atr + MINA (35)	1,2	1,2,3	NS
8	Atr + MINA (60)	1,2,3	1,2,3,7,10	1,7
9	Atr + MINA (100)	NT	1,2,3,4,5,7,8,10	1,4,5,6,7,8
10	Atr + 2-PAM + MINA (35)	1,2,3,4,7	1,2,3	1,4,5,6,7,8
11	Atr + 2-PAM + MINA (60)	1,2,3,4,5,7,8	1,2,3,4,7,10	1,2,4,5,6,7,8,9
12	Atr + 2-PAM + MINA (100)	NT	1,2,3,4,5,7,8,10	1,2,3,4,5,6,7,8,9,10

NS, treatment not significantly more effective in any comparison. NT, treatment not tested.

^a The numbers in each cell group (GRP) comparisons that were significantly more effective from one another.

range, but did not significantly increase from the 13-min to the 58-min scoring time (from 4.50 to 5.50). Administration of a high dose (139.3 mg/kg) of MINA alone (without nerve agent) produced mild toxic signs (average score = 0.67) in the guinea pigs.

Following GB or GF, animals treated with 2-PAM exhibited a similar incidence (100%) of cholinergic toxic signs as that of the saline-treated controls, and had average toxic scores of 3.25 and 4.63, respectively. Guinea pigs exposed to VX and treated with 2-PAM showed a low incidence (38%) of toxic signs and scored significantly lower than saline-treated control animals (0.75 ± 0.37 vs. 3.44 ± 0.75).

The number of GB-exposed animals treated with MINA showing signs of nerve agent intoxication (48%) was significantly smaller (Fisher's exact test, $p < 0.01$) than that of the saline-treated controls (92%). The number of VX-exposed animals treated with MINA showing toxic signs (47%) was not found to be significantly different from saline-treated controls (78%). Animals treated with MINA following GF exposure showed a similar incidence (95%) of toxic signs as that of the saline-treated controls (100%). Additionally, animals treated with MINA at doses of 35.0 mg/kg and above displayed significantly lower toxic sign scores following GB exposure than did the saline-treated controls. Animals treated with MINA at doses of 55.5 and 87.9 mg/kg also displayed significantly lower toxic sign scores following GF and VX exposure, respectively, than did saline-treated controls. No animal treated with 2-PAM or MINA died within 60 min of GB, GF or VX exposure.

3.1.2. AChE activity in brain regions

Table 1 summarizes the ChE reactivation by oxime treatments in brain regions, peripheral tissues and blood components following nerve agent intoxication. Following exposure to GB, ChE activities in the brainstem, cerebellum, cortex, hippocampus, midbrain, spinal cord, and striatum were inhibited to 9%, 6%, 6%, 14%, 8%, 21%, and 14% of control, respectively. As might be expected, 2-PAM did not show any ChE reactivation in the CNS, whereas MINA produced a dose-dependent reactivation of ChE activity in brainstem, cerebellum, cortex, midbrain, and striatum. MINA at doses of 55.5 and 87.9 mg/kg significantly reactivated ChE in brainstem, cerebellum, cortex, midbrain, and striatum, with the 87.9 mg/kg dose also significantly reactivating in the hippocampus. At the highest dose of MINA (139.3 mg/kg) the reactivation of ChE activity in each of the seven CNS regions was highly significant.

Following exposure to GF, ChE activities in the brainstem, cerebellum, cortex, hippocampus, midbrain, spinal cord, and striatum were inhibited to 23%, 13%, 14%, 29%, 19%, 32%, and 28% of control, respectively. 2-PAM did not show any ChE reactivation in the CNS. MINA at doses of 55.5, 87.9 and 139.3 mg/kg produced significant

reactivation of ChE activity in brainstem, midbrain, and spinal cord. Additionally at the dose of 55.5 mg/kg, MINA significantly reactivated ChE in the cerebellum. At the highest dose (139.3 mg/kg) the reactivation of ChE activity in cerebellum, cortex, and hippocampus was also highly significant. MINA did not reactivate GF-inhibited striatal ChE activity at any dose tested.

Following exposure to VX, ChE activities in the brainstem, cerebellum, cortex, hippocampus, midbrain, spinal cord, and striatum were inhibited to 25%, 15%, 10%, 14%, 19%, 32%, and 38% of control, respectively. 2-PAM did not show any ChE reactivation in the CNS. MINA significantly reactivated VX-inhibited ChE activity in the hippocampus at 55.5 and 87.9 mg/kg and in the brainstem, cerebellum, cortex, hippocampus, and midbrain at 139.3 mg/kg.

3.1.3. ChE activity in peripheral tissues and blood

Following exposure to GB, ChE activities in the diaphragm, heart, and skeletal muscle were inhibited to about 20%, 11%, and 23% of control, respectively, and in RBC and WB to about 9% and 11% of control, respectively. In the peripheral tissues and blood, MINA did not produce any reactivation of GB-inhibited ChE at the lower doses (22.1 and 35.0 mg/kg), but did produce significant increases in ChE activity in these tissues at higher doses. MINA significantly reactivated GB-inhibited ChE activity at 55.5, 87.9, and 139.3 mg/kg in the heart, RBC, and WB, and at 87.9 and 139.3 mg/kg in the diaphragm. MINA at doses 55.5 and 139.3 mg/kg also significantly reactivated skeletal muscle ChE. 2-PAM was readily able to reactivate significantly GB-inhibited ChE in all three peripheral tissues (up to 60% of control) and in RBC and WB (to above 60% of control).

Following exposure to GF, ChE activities in the diaphragm, heart, and skeletal muscle were inhibited to about 39%, 24%, and 46% of control, respectively, and in RBC and WB to about 6% and 10% of control, respectively. In the diaphragm, MINA did not produce any reactivation of GF-inhibited ChE at doses of 35.0 mg/kg and below, but did produce significant increases in ChE activity in this tissue at higher doses. MINA significantly reactivated GF-inhibited ChE in heart and WB at doses of 35.0 mg/kg and above. No ChE reactivation was observed in the skeletal muscle or in the RBC by any dose of MINA. 2-PAM was not able to significantly reactivate GF-inhibited ChE in RBC or any of the three peripheral tissues, but was able to significantly reactivate ChE in WB.

Following exposure to VX, ChE activities in the diaphragm, heart, and skeletal muscle were inhibited to about 28%, 23%, and 26% of control, respectively, and in RBC and WB to about 13% and 26% of control, respectively. In the diaphragm, RBC, and WB, MINA produced significant increases in ChE activity only at the highest dose (139.3 mg/kg). In the heart MINA at doses 55.5, 87.9, and 139.3 mg/kg significantly reactivated VX-inhibited ChE. MINA at

doses 22.1 and 139.3 mg/kg was also able to significantly reactivate skeletal muscle ChE. In contrast, 2-PAM was readily able to reactivate VX-inhibited ChE in the diaphragm and heart (up to 45% of control) and in blood (to above 50% of control).

3.1.4. Summary on reactivation of ChE activity

Table 2A–C summarizes the statistically significant ChE reactivation by oxime treatments in the brain regions, the peripheral tissues, and the blood components, respectively, following exposure to GB, GF, and VX. It is striking to notice that MINA was capable of reactivating ChE inhibited by all three nerve agents in brain regions (Table 2A). Following GB exposure, doses of MINA at 35.0 mg/kg and above were able to significantly reactivate inhibited brain ChE. As the dose of MINA increased the ChE activity was reactivated in more brain regions. At the highest dose of 139.3 mg/kg, all seven brain regions displayed significant ChE reactivation. MINA began to show its ability to reactivate ChE when the dose reached 55.5 mg/kg and above following GF exposure. At 55.5 mg/kg ChE activity was significantly reactivated in three brain regions and spinal cord and at 139.3 mg/kg two additional regions showed significant ChE reactivation. In the case of VX, MINA at doses of 55.5 and 87.9 mg/kg significantly reactivated ChE only in the hippocampus. When the dose reached 139.3 mg/kg, four additional brain regions then displayed significant ChE reactivation. The relative ChE reactivating potency of MINA against these nerve agents was GB > GF > VX. 2-PAM did not show any ChE reactivation in the brain.

In three peripheral tissues (Table 2B) MINA reactivated ChE inhibited by GB and GF in at least two peripheral tissues when the dose reached 55.5 mg/kg and above. MINA reactivated VX-inhibited ChE in one peripheral tissue at 22.1, 55.5, and 87.9 mg/kg and all three tissues at 139.3 mg/kg. 2-PAM reactivated GB- and VX-inhibited ChE, but not GF-inhibited ChE, in the peripheral tissues.

In the blood components (RBC and WB) as shown in Table 2C MINA reactivated GB-inhibited ChE in the blood at doses 55.5 mg/kg and above, while only reactivating VX-inhibited ChE in the blood at 139.3 mg/kg. At 35.0 mg/kg and above, MINA reactivated GF-inhibited ChE only in the WB. 2-PAM reactivated GB- and VX-inhibited ChE in the RBC and WB, but only reactivated GF-inhibited ChE in the WB.

Overall, the capability of MINA to reactivate ChE activity in peripheral tissues and brain inhibited by these three nerve agents was in the order of GB > GF > VX.

3.2. Survival experiments

Table 3A shows the 24-h LD₅₀s and LD₅₀ ratios for various treatment regimens after GB, GF, or VX intoxication, while Table 3B displays the statistical significance comparisons among treatment groups. Against all three nerve agents, treatment with atropine sulfate (0.5 mg/kg, i.m.) alone was ineffective and resulted in LD₅₀s that were not different from our previously reported LD₅₀ estimates of the nerve agent alone [3,21,30]. Following lethal GB intoxication, 2-PAM treatment alone was 2-fold more efficacious than atropine sulfate therapy. MINA at 35.0 mg/kg was significantly more efficacious than atropine sulfate or 2-PAM treatment alone, and was equivalent to, or as effective as atropine sulfate + 2-PAM treatment against the lethal effects of GB intoxication. MINA displayed a significant dose-dependent therapeutic efficacy against GB intoxication at doses from 35.0 to 60.0 mg/kg. Addition of atropine sulfate to MINA treatment did not enhance the protection afforded by MINA treatment alone at respective MINA doses. In combination with atropine sulfate, MINA at a dose of 60.0 mg/kg was 2.4 times more protective than atropine sulfate + 2-PAM treatment. MINA was most effective when added to atropine sulfate + 2-PAM treatment regimen. In these combination (atropine + 2-PAM + MINA) treatment groups, there was a 4.3- to 5.1-fold increase in the LD₅₀

of GB compared to the GB LD₅₀ in the atropine sulfate + 2-PAM treatment group.

In the case of lethal GF exposure, 2-PAM treatment alone or atropine + 2-PAM treatment did not afford any protection. Higher doses (60.0 and 100.0 mg/kg) of MINA were required to produce significant dose-dependent efficacy against the lethal effects of GF. These two doses of MINA alone were significantly more efficacious than either atropine sulfate treatment alone or 2-PAM treatment alone against GF intoxication. However, addition of atropine sulfate or even atropine sulfate + 2-PAM did not result in greater protection. The protection against the lethal effects of GF was primarily provided by MINA treatment.

Following VX intoxication, 2-PAM treatment alone or atropine + 2-PAM treatment provided significant protection when compared with atropine sulfate treatment alone. MINA required a dose of 100.0 mg/kg to afford some protection. Treatment at this highest dose (100.0 mg/kg) of MINA alone or in combination with atropine sulfate provided significantly greater protection than atropine sulfate treatment alone. When MINA was combined with atropine sulfate + 2-PAM, all three doses of MINA provided significant dose-dependent protection against lethal VX exposure. Overall, the protective efficacy of MINA against the lethal effects of these three nerve agents was in the order of GB > GF > VX.

4. Discussion

Under the conditions of this study, both quaternary (2-PAM) and tertiary (MINA) oximes were able to reactivate GB-, GF-, or VX-inhibited ChE in a dose-related manner, but with notable variations with respect to tissue specificity. 2-PAM and the higher doses of MINA reactivated nerve agent-inhibited ChE in the blood or peripheral tissues, with the action of MINA much weaker than that of 2-PAM against GB or VX. 2-PAM only reactivated GF-inhibited ChE in WB. Only MINA reactivated AChE in the CNS. The reactivating potency of MINA was in the order of GB > GF > VX.

The present results demonstrate the benefit of reactivating CNS ChE with an oxime on survival outcomes following nerve agent intoxication. MINA's capacity to increase survival outcomes in these studies, in general, paralleled its potency in reactivating brain ChE. This was most clearly demonstrated when it was combined with 2-PAM. The increased survival outcomes provided by MINA in 2-PAM-treated animals was most likely due to reactivation of brain ChE. Even a small amount of ChE reactivation in the CNS by MINA significantly increased the efficacy. This was suggested by the benefit that MINA provided in GF- or VX-intoxicated animals treated with atropine sulfate plus 2-PAM.

Tertiary oximes like MINA are much less potent reactivators of phosphorylated ChE than are pyridinium and bis-pyridinium oximes [9,14]. Therefore, it was not surprising that the effective reactivating doses of MINA (637.0–1600.1 μ mol/kg) used in this study against GB were 3–12 times higher on micromolar basis than was 2-PAM (145.0 μ mol/kg). Metabolism of MINA generates cyanide, which is thought to be responsible for the toxic effect of this oxime [9]. The highest dose of MINA (139.3 mg/kg) used in the present study, although not sign-free, was not a lethal dose in guinea pigs (unpublished data).

MINA was a weaker reactivator of VX- and GF-inhibited ChE than of GB-inhibited ChE, and a weaker reactivator of peripheral ChE than of CNS ChE for all three nerve agents. The ChE reactivation capacity in the presence of VX in the CNS was only observed in very limited brain regions and only at very high doses of MINA when compared with those of GB or GF. Subsequently, only at the highest dose was either MINA treatment alone or MINA in combination with atropine sulfate + 2-PAM observed to provide significant protection against lethal doses of VX. Since the toxic effects of VX take a longer time to develop [3,30], MINA would be expected to

have the advantage of reaching the blood and neuromuscular and synaptic junctional ChE pools, placing it in prime position to react with and degrade VX when it arrives. However, this was not the case in the present study. The reason for weaker action of MINA in reactivating VX-induced ChE activity was unclear, but could be due to several factors. The most likely explanation is that MINA has less affinity and reactivity as a reactivator of VX-inhibited ChE than it has as a reactivator of GB-inhibited ChE.

It is unclear why MINA reactivated GF-inhibited ChE in this study. GF-inhibited ChE, in general, is more difficult to reactivate with oximes than are GB- and VX-inhibited ChE [22]. Some very potent oximes, relative to MINA, such as 2-PAM, obidoxime, and TMB-4 (trimedoxime) are relatively poor reactivators of GF-inhibited ChE [22]. In this study 2-PAM was not able to reactivate GF-inhibited ChE in the RBC, brain regions, and three peripheral tissues, and, therefore, provided little or no protection against lethal effects of GF. On the contrary, MINA was capable of reactivating ChE inhibited by GF in blood, brain regions, diaphragm, and heart and also provided marked protection when given at doses of 60.0 or 100.0 mg/kg at 1 min after varying LD₅₀ doses of GF. In this instance, the addition of atropine sulfate and atropine + 2-PAM to MINA treatment did not provide additional protection, thus, suggesting the importance of elevated brain ChE activity as a result of reactivation by MINA, the sole contributor to the therapeutic efficacy.

MINA markedly reactivated ChE activity in blood, peripheral tissues, and multiple brain regions following GB intoxication, even at the lowest dose (35.0 mg/kg) of MINA tested. Consequently, its treatment alone without atropine sulfate was more efficacious than atropine sulfate alone, 2-PAM alone, or even the combination of atropine sulfate + 2-PAM (i.e., compared with 60.0 mg/kg of MINA treatment alone). Additionally, MINA alone was just as effective as MINA + atropine sulfate treatment. This implies that the antidotal requirements of CNS ChE activity are critical and thus, places the blocking of CNS muscarinic receptors by anticholinergic drug in a secondary role. The most dramatic benefit from the use of MINA occurred when it was used in combination with atropine sulfate + 2-PAM treatment. In these combination treatment groups, approximately 10–20% reactivation of CNS ChE by MINA in concert with the peripheral ChE reactivation by MINA and 2-PAM and a small dose of atropine sulfate (0.5 mg/kg, i.m.) to block muscarinic receptors resulted in large increases in survival. This further suggests that ChE, especially brain ChE, reactivation should be the root of medical countermeasures in nerve agent poisoning. Thus, a centrally active oxime will be most beneficial if it is able to reactivate ChE inhibited by a broad spectrum of nerve agents.

Conflicts of interest statement

The authors declare that there are no conflicts of interest.

Acknowledgements

The authors wish to recognize the excellent technical assistance of Anna Smelley, Cindy Acon-Chen, Jeff Koenig, Kerry VanShura, Susan Schulz, and Dr. John Guarisco. This research was supported by the Defense Threat Reduction Agency – Joint Science and Technology Office, Medical Science and Technology Division.

References

[1] P. Taylor, Anticholinesterase agents, in: J.G. Hardman, L.E. Limbird, A.G. Gilman (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed., McGraw-Hill, NY, 2001, pp. 175–191.

[2] J.H. McDonough, T.-M. Shih, Neuropharmacological mechanisms of nerve agent induced seizure and neuropathology, *Neurosci. Biobehav. Rev.* 21 (1997) 559–579.

[3] T.-M. Shih, S.M. Duniho, J.H. McDonough, Control of nerve agents-induced seizures is critical for neuroprotection and survival, *Toxicol. Appl. Pharmacol.* 188 (2003) 69–80.

[4] I.B. Wilson, S. Ginsburg, A powerful reactivator of alkylphosphate-inhibited acetylcholinesterase, *Biochem. Biophys. Acta* 18 (1955) 168–170.

[5] D.H. Moore, C.B. Clifford, I.T. Crawford, G.M. Cole, J.M. Baggett, Review of nerve agent inhibitors and reactivators of acetylcholinesterase, in: D.M. Quinn, A.S. Balasubramanian, B.P. Doctor, P. Taylor (Eds.), *Enzymes of the Cholinesterase Family*, Plenum Press, NY, 1995, pp. 297–304.

[6] P. Aas, Future considerations for the medical management of nerve-agent intoxication, *Prehosp. Disaster Med.* 18 (2003) 208–216.

[7] E.M. Cohen, H. Wiersinga, Oximes in the treatment of nerve gas poisoning, *Acta Physiol. Pharmacol.* 9 (1960) 276–302.

[8] J.P. Rutland, The effect of some oximes in sarin poisoning, *Br. J. Pharmacol.* 13 (1958) 399–403.

[9] B.M. Askew, Oximes and hydroxamic acids as antidotes in anticholinesterase poisoning, *Br. J. Pharmacol.* 11 (1956) 417–423.

[10] B.M. Askew, Oximes and atropine in sarin poisoning, *Br. J. Pharmacol.* 12 (1957) 340–343.

[11] L. Dultz, M.A. Epstein, G. Freeman, E.H. Gray, W.B. Weil, Studies on a group of oximes as therapeutic compounds in sarin poisoning, *J. Pharmacol. Exp. Ther.* 119 (1957) 522–531.

[12] D.K. Myers, Mechanism of the prophylactic action of diacetylmonoxime against sarin poisoning, *Biochem. Biophys. Acta* 34 (1959) 555–557.

[13] J.H. Wills, Recent studies of organic phosphate poisoning, *Fed. Proc.* 18 (1959) 1020–1025.

[14] F. Hobbiger, Reactivation of phosphorylated acetylcholinesterase, in: G.B. Koelle (Ed.), *Cholinesterases and Anticholinesterase Agents*, Handbuch der Experimentellen Pharmakologie, Springer-Verlag, Berlin, 1963, pp. p921–988.

[15] T.-M. Shih, D.M. Maxwell, I. Koplovitz, R.K. Kan, J.H. McDonough, Reactivation of acetylcholinesterase activity and its therapeutic benefits in nerve agent intoxication, in: B.A. Weissman, L. Laveh (Eds.), *The Neurochemical Consequences of Organophosphate Poisoning in the CNS*, Transworld Research Network, India, 2010, Chapter 7, ISBN number: 978-81-7895-464-6, in press.

[16] T.-M. Shih, J.W. Skovira, J.C. O'Donnell, J.H. McDonough, Central acetylcholinesterase reactivation by oximes improves survival and terminates seizures following nerve agent intoxication, *Adv. Stud. Biol.* 1 (2009) 155–196.

[17] P. Fosbraey, J.R. Wetherell, M.C. French, Effect of acute physostigmine-hyoscine pretreatment on the neurochemical changes produced by soman in the guinea pig, *Neurochem. Int.* 18 (1992) 265–272.

[18] J.R. Wetherell, Continuous administrations of low dose rates of physostigmine and hyoscine to guinea pigs prevents the toxicity and reduces the incapacitation produced by soman poisoning, *J. Pharm. Pharmacol.* 71 (1994) 1023–1027.

[19] J.R. Wetherell, T. Hall, S. Passingham, Physostigmine and hyoscine improves protection against the lethal and incapacitating effects of nerve agent poisoning in the guinea pig, *NeuroToxicology* 23 (2002) 341–349.

[20] T.-M. Shih, R.K. Kan, J.H. McDonough, *In vivo* cholinesterase inhibitory specificity of organophosphorus nerve agents, *Chem. Biol. Interact.* 157–158 (2005) 293–303.

[21] A.A. Vallejo-Freire, A simple technique for repeated collection of blood samples from guinea pigs, *Science* 114 (1951) 524–525.

[22] T.-M. Shih, J.W. Skovira, J.C. O'Donnell, J.H. McDonough, Evaluation of nine oximes on *in vivo* reactivation of blood, brain and tissue cholinesterase activity inhibited by organophosphorus nerve agent at a lethal dose, *Toxicol. Mech. Methods* 19 (2009) 386–400.

[23] G.L. Ellman, K.D. Courtney, V. Andres, R.M. Featherstone, A new and rapid colorimetric determination of acetylcholinesterase activity, *Biochem. Pharmacol.* 7 (1961) 88–95.

[24] P.I. Feder, D.W. Hobson, C.T. Olson, R.L. Joiner, M.C. Matthews, Staged, adaptive dose allocation for quantal response dose–response studies, *Neurosci. Biobehav. Rev.* 15 (1991) 109–114.

[25] P.I. Feder, C.T. Olson, D.W. Hobson, M.C. Matthews, R.L. Joiner, Staged, group sequential experimental designs for quantal responses, one-sample and two-sample comparisons, *Neurosci. Biobehav. Rev.* 15 (1991) 129–133.

[26] P.I. Feder, C.T. Olson, D.W. Hobson, M.C. Matthews, Statistical analysis of dose–response experiments by maximum likelihood analysis and iteratively reweighted nonlinear least squares techniques, *Drug Inform. J.* 25 (1991) 323–334.

[27] D.J. Finney, *Probit Analysis*, 3rd ed., Cambridge Univ. Press, Cambridge, England, 1971.

[28] Food and Drug Administration Guidance for Industry, Estimating the maximum safe starting dose in initial clinical trials for therapeutics in health human volunteers, Division of Drug Information, HFD-240, Center for Drug and Research Evaluation, 2005, <http://www.fda.gov/cder/guidance/index/htm>.

[29] G. Hurst, S. Tuorinsky, J. Madsen, J. Newmark, B. Hill, C. Boardman, J. Dawson, Medical Management of Chemical Casualties Handbook, 4th ed., U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, 2007.

[30] T.-M. Shih, T. Rowland, J.H. McDonough, Anticonvulsants for nerve agent-induced seizures: the influence of the therapeutic dose of atropine, *J. Pharmacol. Exp. Ther.* 320 (2007) 154–161.